Kean, LS, Burns, LJ, Kou, TD, et al. Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation. Blood 144:17 (2024), 1834–1845.
Storb, R, Antin, JH, Cutler, C, Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease?. Biol Blood Marrow Transplant 16:suppl 1 (2010), S18–S27.
Finke, J, Bethge, WA, Schmoor, C, et al., ATG-Fresenius Trial Group. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 10:9 (2009), 855–864.
Jamy, O, Zeiser, R, Chen, Y-B, Novel developments in the prophylaxis and treatment of acute GVHD. Blood 142:12 (2023), 1037–1046.
Bolaños-Meade, J, Hamadani, M, Wu, J, et al., BMT CTN 1703 Investigators. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med 388:25 (2023), 2338–2348.
Battipaglia, G, Labopin, M, Kröger, N, et al. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood 134:11 (2019), 892–899.
Watkins, B, Qayed, M, McCracken, C, et al. Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD. J Clin Oncol 39:17 (2021), 1865–1877.
